Regeneron Pharmaceuticals (REGN)
$298.11 0.00 (0.00%)
4:00 EDT REGN Stock Quote Delayed 15 Minutes
Previous Close $298.11
Market Cap 31.58B
PE Ratio 24.16
Volume (Avg. Vol.)
Day's Range 298.11 - 298.11
52-Week Range 287.66 - 442.00
Dividend & Yield N/A (N/A)
REGN Stock Predictions, Articles, and Regeneron Pharmaceuticals News
- From InvestorPlace
- From the Web
Investors saw new highs in the Nasdaq today, but the index finished slightly lower on the day. Here's what we're watching now.
Trump says that Facebook and Alphabet should be sued, while Micron surged on earnings. Semiconductors got a big boost in the Nasdaq today as well.
Government is scrutinizing the drug development and approval process and creating uncertainties among biotech stocks. Time to buy?
Regeneron Pharmaceuticals earnings for the first quarter of 2019 have REGN stock falling on Tuesday due to poor results for the period.
Biotech stocks fell sharply in the last few weeks, mostly on no new news. This drop may have created an entry point for investors.
While some companies are doing a good job closing their CEO-Worker wage gaps, these seven companies are not.
When drug companies fall out of favor, as now, I look first to companies with a method for drug discovery like Regeneron stock.
Big pharma stocks are getting good coverage from JPMorgan's healthcare event. Here are three undervalued pharmaceutical stocks to buy now.
It might seem like an odd pairing, but WING and REGN stock have similar leadership qualities off and on the price chart.
The best stocks to buy at the bottom of a bear market are those you can see growing over the next three to five years.
Teva stock is now at yearly lows, a victim of negative macro news, falling stock markets, and year-end tax-loss selling.
Despite their indispensable demand, pharmaceutical stocks face tough roadblocks as competition for breakthrough drugs intensifies.
Biogen stock reaffirmed its dominance in MS and the neurosciences market. At a low P/E mutliple, investors should look at BIIB again.
Thanks to advancing technologies and a generally positive economy, healthcare stocks are back in the limelight.
These five biotech stocks balance low valuation with high growth and a track record of profits.
Sometimes seemingly deadbeat stocks still have more life left in them despite what the Street thinks. Here are seven rebounding stocks that have the support of top analysts.
Pfizer renewed the drug price hike cycle after it raised them for around 40 products. If other biotech stocks follow, profits will soar.
From The Street
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Twilio Inc (TWLO), where a total of 19,119 contracts have traded so far, representing approximately 1.9 million underlying shares. That amounts to about 58.5% of TWLO's average daily trading volume over the past month of 3.3 million shares..
Navellier RatingsPowered by Portfolio Grader
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!